People Briefs: Mercator, MITA And 23andMe
This article was originally published in The Gray Sheet
Executive Summary
Drug-delivery firm Mercator MedSystems names a new CEO. Also, recent appointments at MITA and 23andMe.
You may also be interested in...
FDA Comes Down Hard On 23andMe, Putting Consumer-Directed Genetic Testing On Notice
The agency tells direct-to-consumer genetic testing company 23andMe in a strongly-worded warning letter that it should immediately stop marketing its Personal Genome Service until it can gain clearance. The firm says it will address the agency’s concerns.
Abbott Ups Vascular, Ophthalmic Focus With Two Acquisitions
Abbott Laboratories announced July 15 it has entered into agreements to purchase stent manufacturer IDev Technologies and ophthalmic device company OptiMedica Corp. The acquisitions are intended to bolster the company’s medical device unit in the vascular and vision care businesses, respectively.
Keeping Track: Return & Renewal At US FDA
Takeda’s TAK-721 is back, ARS Pharma will be back soon to appeal neffy complete response letter, US FDA’s Project Renewal brings Temodar labeling in current day, and more highlights from the Pink Sheet’s US FDA Performance Tracker.